trihydroxy-[1,4]benzoquinone | 1760-50-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trihydroxy-[1,4]benzoquinone
• 英文别名: Trihydroxy-[1,4]benzochinon；Trihydroxybenzoquinone；2,3,5-trihydroxycyclohexa-2,5-diene-1,4-dione
• CAS: 1760-50-5
• 化学式: C₆H₄O₅
• 分子量: 156.095
• InChiKey: JUJQEGMCTDBMGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Process and intermediates for the manufacture of optically active chroman derivatives
  申请人：ASAHI DENKA KOGYO KABUSHIKI KAISHA

  公开号：EP0441116A2

  公开（公告）日：1991-08-14

  An optically active (S)- or (R)-chroman-2-ethanol compound of the general formula (I) wherein R₁, R₂ and R₃ independently represent a hydrogen atom or a lower alkyl group having 1 to 4 carbon atoms, and the chiral central carbon atom marked with a symbol * in the formula (I) alternatively has one of an R-configuration and an S-configuration, is disclosed. Further, intermediate products of the compound of the formula (I) are also disclosed. Still further, a process for manufacturing the above compounds is disclosed. The compound of the formula (I) is easily synthesized from an easily available optically active starting material.

  通式(I)的具有光学活性的(S)-或(R)-色满-2-乙醇化合物 其中 R₁、R₂ 和 R₃ 独立地代表氢原子或具有 1 至 4 个碳原子的低级烷基，且式 (I) 中标记为符号 * 的手性中心碳原子具有 R 构型和 S 构型中的一种。此外，还公开了式 (I) 化合物的中间产物。此外，还公开了制造上述化合物的工艺。式（I）化合物很容易从易于获得的光学活性起始材料中合成。
• Formulation and process for modulating wound healing
  申请人：BioMendics, LLC

  公开号：US10426742B2

  公开（公告）日：2019-10-01

  Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably trans); or —CRa═CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q; R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≥1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.

  本发明公开了通过调节自噬促进伤口愈合的方法和化合物。用于调节自噬的制剂包括选自具有一般结构 (I) 的化合物的第一调节化合物 (FAM)： 其中L 代表选自-C≡C-（甲苯）、-CH═CH-（二苯乙烯，最好是反式）或-CRa═CRb-二苯乙烯衍生物的连接体；其中 Ra 和 Rb 独立地是 H 或任选被-(R3)p 或-(R4)q 取代的苯基； R1至R4是独立的取代基，位于苯基环的任何可用位置，优选位于3，3′、4，4′和/或5，5′；m、n、p和q分别独立地为0、1、2或3，代表环的取代基数目，但m或n中至少有一个必须≥1。每个 R1 至 R2 独立地选自本文所述的取代基，包括但不限于羟基、烷氧基、卤代、卤代甲基和苷。制剂还可包括本文所述的辅助自噬调节化合物（AAM）。制剂可包括由化合物本身或以其它方式形成的水凝胶，并可包括盐和/或复合物。
• FORMULATION AND PROCESS FOR MODULATING WOUND HEALING
  申请人：Biomendics LLC

  公开号：EP3280402A2

  公开（公告）日：2018-02-14
• Formulation and Process for Modulating Wound Healing
  申请人：BioMendics, LLC

  公开号：US20160296477A1

  公开（公告）日：2016-10-13

  Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably trans); or —CR a ═CR b — a stilbene derivative; where R a and R b are independently H or phenyl optionally substituted with —(R 3 ) p or —(R 4 ) q ; R 1 to R 4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≧1. Each R 1 to R 2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.
• US5233056A
  申请人：——

  公开号：US5233056A

  公开（公告）日：1993-08-03